Maze Therapeutics Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Maze Therapeutics Inc Company

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.

Maze Therapeutics Inc Info



Ticker SymbolMAZE

Company nameMaze Therapeutics Inc

IPO dateJan 31, 2025

CEODr. Jason V. Coloma, Ph.D.

Number of employees125

Security typeOrdinary Share

Fiscal year-endJan 31

Address171 Oyster Point Boulevard, Suite 300

CitySOUTH SAN FRANCISCO

Stock exchangeNASDAQ Global Market Consolidated

CountryUnited States of America

Postal code94080

Phone16508505070

Websitehttps://www.mazetx.com/

Ticker SymbolMAZE

IPO dateJan 31, 2025

CEODr. Jason V. Coloma, Ph.D.

Company Executives of Maze Therapeutics Inc



Name

Name/Position

Position

Shareholding

Change

Dr. Jonathan E. Lim, M.D.

Independent Director

328.70K

--

Dr. Sekar (Sek) Kathiresan, M.D.

Independent Director

103.72K

--

Mr. Atul Dandekar

Chief Strategy and Business Officer

8.94K

--

Mr. Neil Exter

Independent Director Nominee

--

Dr. Charles Homcy, M.D.

Co-Founder, Director

--

Dr. Jason V. Coloma, Ph.D.

Chief Executive Officer, Director

--

Mr. Alan B. Colowick, M.D.

Independent Director

--

Dr. Richard H. Scheller, Ph.D.

Independent Director

--

-100.00%

Ms. Jillian Connell

Investor Relations

--

Dr. Jamie Brush, M.D.

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Dr. Jonathan E. Lim, M.D.

Independent Director

328.70K

--

Dr. Sekar (Sek) Kathiresan, M.D.

Independent Director

103.72K

--

Mr. Atul Dandekar

Chief Strategy and Business Officer

8.94K

--

Mr. Neil Exter

Independent Director Nominee

--

Dr. Charles Homcy, M.D.

Co-Founder, Director

--

Dr. Jason V. Coloma, Ph.D.

Chief Executive Officer, Director

--

Revenue Breakdown

FY2025Q2

FY2024

No Data

By RegionUSD

Name

Revenue

Proportion

United States

0.00

0.00%

By Business

By Region

No Data

Shareholding Stats

Updated: Mon, Nov 10

Shareholders

Shareholder Types

Shareholders

Proportion

Third Rock Ventures, LLC

11.27%

Frazier Life Sciences Management, L.P.

9.49%

ARCH Venture Partners

8.56%

Deep Track Capital LP

8.21%

Matrix Capital Management Company, LP

5.17%

Other

57.30%

Shareholders

Proportion

Third Rock Ventures, LLC

11.27%

Frazier Life Sciences Management, L.P.

9.49%

ARCH Venture Partners

8.56%

Deep Track Capital LP

8.21%

Matrix Capital Management Company, LP

5.17%

Other

57.30%

Shareholder Types

Shareholders

Proportion

Venture Capital

31.81%

Private Equity

14.60%

Hedge Fund

13.75%

Investment Advisor/Hedge Fund

10.99%

Investment Advisor

6.38%

Individual Investor

1.88%

Endowment Fund

1.32%

Family Office

1.00%

Pension Fund

0.05%

Other

18.21%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

111

39.53M

83.57%

-194.63K

2025Q2

100

42.58M

97.22%

+13.88M

2025Q1

93

44.69M

102.04%

+15.27M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Third Rock Ventures, LLC

7.02M

16.02%

--

Jun 30, 2025

Frazier Life Sciences Management, L.P.

4.57M

10.42%

+115.94K

+2.60%

Jun 30, 2025

ARCH Venture Partners

4.12M

9.4%

--

Jun 30, 2025

Deep Track Capital LP

3.95M

9.01%

+679.78K

+20.79%

Jun 30, 2025

Matrix Capital Management Company, LP

2.49M

5.67%

--

Jun 30, 2025

Foresite Capital Management, LLC

2.46M

5.6%

--

Jun 30, 2025

Alphabet, Inc.

2.41M

5.5%

--

Jun 30, 2025

Andreessen Horowitz

1.70M

3.88%

--

Jun 30, 2025

Janus Henderson Investors

1.40M

3.2%

+154.89K

+12.43%

Jun 30, 2025

The Vanguard Group, Inc.

419.61K

0.96%

-246.94K

-37.05%

Jun 30, 2025

Related ETFs



Updated: Thu, Nov 6

Name

Proportion

Virtus LifeSci Biotech Clinical Trials ETF

1.38%

ALPS Medical Breakthroughs ETF

0.44%

Invesco Dorsey Wright SmallCap Momentum ETF

0.42%

iShares Micro-Cap ETF

0.1%

iShares Russell 2000 Value ETF

0.03%

Proshares Ultra Russell 2000

0.02%

ProShares UltraPro Russell2000

0.02%

ProShares Hedge Replication ETF

0.02%

Global X Russell 2000 ETF

0.02%

iShares Russell 2000 ETF

0.01%

Virtus LifeSci Biotech Clinical Trials ETF

Proportion1.38%

ALPS Medical Breakthroughs ETF

Proportion0.44%

Invesco Dorsey Wright SmallCap Momentum ETF

Proportion0.42%

iShares Micro-Cap ETF

Proportion0.1%

iShares Russell 2000 Value ETF

Proportion0.03%

Proshares Ultra Russell 2000

Proportion0.02%

ProShares UltraPro Russell2000

Proportion0.02%

ProShares Hedge Replication ETF

Proportion0.02%

Global X Russell 2000 ETF

Proportion0.02%

iShares Russell 2000 ETF

Proportion0.01%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data